(2S,3S)-2,3-Bis-[(E)-3-(3,4-dihydroxy-phenyl)-acryloyloxy]-succinic acid

ID: ALA29660

Chembl Id: CHEMBL29660

Cas Number: 52248-48-3

PubChem CID: 5470299

Max Phase: Preclinical

Molecular Formula: C22H18O12

Molecular Weight: 474.37

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Synonyms: chicoric acid | D-chicoric acid | D-Chicoric acid|D-DCTA|Dicaffeoyl-D-tartaric acid|52248-48-3|NSC 699176|CHEMBL29660|NSC699176|(1S,2S)-1,2-Bis(3-(3,4-dihydroxyphenyl)prop-2-enoyloxy)ethane-1,2-dicarboxylic acid|(2S,3S)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid|Butanedioic acid, 2,3-bis(((2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-, (2S,3S)-|(1S,2S)-1,2-Bis[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]ethane-1,2-dicarboxylic acid|Butanedioic acid, 2,3-bis[[(2E)-3-(3,Show More

Canonical SMILES:  O=C(/C=C/c1ccc(O)c(O)c1)O[C@H](C(=O)O)[C@H](OC(=O)/C=C/c1ccc(O)c(O)c1)C(=O)O

Standard InChI:  InChI=1S/C22H18O12/c23-13-5-1-11(9-15(13)25)3-7-17(27)33-19(21(29)30)20(22(31)32)34-18(28)8-4-12-2-6-14(24)16(26)10-12/h1-10,19-20,23-26H,(H,29,30)(H,31,32)/b7-3+,8-4+/t19-,20-/m0/s1

Standard InChI Key:  YDDGKXBLOXEEMN-QFZCZCNSSA-N

Alternative Forms

  1. Parent:

Associated Targets(Human)

CEM-SS (2428 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MT4 (17854 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MT2 (2907 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

pol Human immunodeficiency virus type 1 integrase (9041 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Human immunodeficiency virus 1 (70413 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
P388 (20296 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
botA Botulinum neurotoxin type A (1303 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 474.37Molecular Weight (Monoisotopic): 474.0798AlogP: 1.23#Rotatable Bonds: 9
Polar Surface Area: 208.12Molecular Species: ACIDHBA: 10HBD: 6
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 6#RO5 Violations (Lipinski): 2
CX Acidic pKa: 2.72CX Basic pKa: CX LogP: 3.02CX LogD: -3.15
Aromatic Rings: 2Heavy Atoms: 34QED Weighted: 0.17Np Likeness Score: 0.71

References

1. Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin JA, Aberham C, Strebel K, Kohn K, Witvrouw M, Pannecouque C, Debyser Z, De Clercq E, Rice WG, Pommier Y, Burke TR..  (1999)  Chicoric acid analogues as HIV-1 integrase inhibitors.,  42  (8): [PMID:10212126] [10.1021/jm980531m]
2. King PJ, Ma G, Miao W, Jia Q, McDougall BR, Reinecke MG, Cornell C, Kuan J, Kim TR, Robinson WE..  (1999)  Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.,  42  (3): [PMID:9986720] [10.1021/jm9804735]
3. Queffélec C, Bailly F, Mbemba G, Mouscadet JF, Debyser Z, Witvrouw M, Cotelle P..  (2008)  The total synthesis of fukiic acid, an HIV-1 integrase inhibitor.,  43  (10): [PMID:18243421] [10.1016/j.ejmech.2007.12.013]
4. Burgess EJ, Larsen L, Perry NB..  (2000)  A cytotoxic sesquiterpene caffeate from the liverwort Bazzanianovae-zelandiae.,  63  (4): [PMID:10785435] [10.1021/np990492x]
5. Silhár P, Lardy MA, Hixon MS, Shoemaker CB, Barbieri JT, Struss AK, Lively JM, Javor S, Janda KD..  (2013)  The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.,  (2): [PMID:23565325] [10.1021/ml300428s]
6. Zhao Y, Gu Q, Morris-Natschke SL, Chen CH, Lee KH..  (2016)  Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.,  59  (19): [PMID:27676157] [10.1021/acs.jmedchem.6b00461]
7. Zhou Y, McGillick BE, Teng YG, Haranahalli K, Ojima I, Swaminathan S, Rizzo RC..  (2016)  Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarity.,  24  (20): [PMID:27543389] [10.1016/j.bmc.2016.07.031]

Source